Life Sciences & Healthcare  Newsletters

Kempen European Life Sciences ECM update 

  • Monthly update on Equity Capital Markets of European Life Sciences companies
  • Provides insights on market developments, financing transactions, share price developments and other relevant insights in the field of ECM
  • Example analysis from the March 2019 ECM update below

EU Life Sciences ABB* volume over the last five years

 EU Life Sciences ABB* volume over the last five years 
  • Over the last five years, the number of accelerated bookbuild offerings executed per year varied between 15-26 deals, with an average size between €44.7 - €80.5m
  • Three ABB transactions were executed in the first two months of 2019 (Biocartis, €55.5m; Oncopeptides, €53.3m; Nordic Nanovector, €22.9m), compared to one transaction in the same period in 2018
  • In 2015, over 50% of total ABB volume was raised in the first two months of the year, compared to 23% in 2016, 0% in 2017 and 3% in 2018 

*Accelerated bookbuild offering
Source: Bloomberg, Kempen analysis as per 28 February 2019; included are Life Sciences deals on European regulated stock exchanges excluding United Kingdom (>€10m)

Kempen European Life Sciences M&A update

  • Bi-monthly update on Mergers & Acquisitions of European Life Sciences companies
  • Provides insights on the current M&A climate, recent developments, transactions and other relevant insights in the field of M&A
  • Example analysis from the March 2019 M&A update below

Europeans buy most European Life Sciences companies, but China and Japan are becoming increasingly active

 Europeans buy most European Life Sciences companies, but China and Japan are becoming increasingly active

  • On average, almost 2/3 of all Life Sciences M&A targets in Europe is acquired by European bidders and close to a quarter by North-American bidders
  • Interestingly, although numbers are still relatively small, the activity of Chinese and Japanese acquirers in European M&A has more than doubled since 2015, despite a drop in overall M&A volume 

Footnote 1: Included are transactions involving a European target. Analysis is performed based on disclosed deal information. Minority stakes, and deal transactions below €25m are excluded.

Sources: Mergermarket, Bloomberg, Kempen Analysis

Subscribe now

Leave your company email address here to receive our Life Sciences & Healthcare Newsletters